Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William L Ince

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Antiviral Research|April 12, 2019
Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conferenceJohn H Beigel, Hannah H Nam, Peter L Adams, et al.
Journal of Virology|June 5, 2009
Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouseShailesh K Choudhary, Naser L Rezk, William L Ince, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 23, 2011
Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategySuman R Das, Scott E Hensley, Alexandre David, et al.
Antimicrobial Agents and Chemotherapy|March 9, 2022
Pleiotropic Effects of Influenza H1, H3, and B Baloxavir-Resistant Substitutions on Replication, Sensitivity to Baloxavir, and Interferon ExpressionBrady T Hickerson, Simone E Adams, Subrata Barman, et al.
Plos Pathogens|January 19, 2018
Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costsIvan Kosik, William L Ince, Lauren E Gentles, et al.
Plos Pathogens|June 21, 2018
Correction: Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costsIvan Kosik, William L Ince, Lauren E Gentles, et al.
Journal of Virology|February 13, 2009
Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalizationWilliam L Ince, Patrick R Harrington, Gretja L Schnell, et al.
Cell Host & Microbe|March 19, 2013
Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selectionSuman R Das, Scott E Hensley, William L Ince, et al.
Journal of the National Cancer Institute|July 7, 2005
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumabWilliam L Ince, Adrian M Jubb, Scott N Holden, et al.
Plos Pathogens|June 20, 2014
Biogenesis of influenza a virus hemagglutinin cross-protective stem epitopesJavier G Magadán, Meghan O Altman, William L Ince, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Antiviral Research|April 12, 2019
Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conferenceJohn H Beigel, Hannah H Nam, Peter L Adams, et al.
Journal of Virology|June 5, 2009
Suppression of human immunodeficiency virus type 1 (HIV-1) viremia with reverse transcriptase and integrase inhibitors, CD4+ T-cell recovery, and viral rebound upon interruption of therapy in a new model for HIV treatment in the humanized Rag2-/-{gamma}c-/- mouseShailesh K Choudhary, Naser L Rezk, William L Ince, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 23, 2011
Fitness costs limit influenza A virus hemagglutinin glycosylation as an immune evasion strategySuman R Das, Scott E Hensley, Alexandre David, et al.
Antimicrobial Agents and Chemotherapy|March 9, 2022
Pleiotropic Effects of Influenza H1, H3, and B Baloxavir-Resistant Substitutions on Replication, Sensitivity to Baloxavir, and Interferon ExpressionBrady T Hickerson, Simone E Adams, Subrata Barman, et al.
Plos Pathogens|January 19, 2018
Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costsIvan Kosik, William L Ince, Lauren E Gentles, et al.
Plos Pathogens|June 21, 2018
Correction: Influenza A virus hemagglutinin glycosylation compensates for antibody escape fitness costsIvan Kosik, William L Ince, Lauren E Gentles, et al.
Journal of Virology|February 13, 2009
Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalizationWilliam L Ince, Patrick R Harrington, Gretja L Schnell, et al.
Cell Host & Microbe|March 19, 2013
Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selectionSuman R Das, Scott E Hensley, William L Ince, et al.
Journal of the National Cancer Institute|July 7, 2005
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumabWilliam L Ince, Adrian M Jubb, Scott N Holden, et al.
Plos Pathogens|June 20, 2014
Biogenesis of influenza a virus hemagglutinin cross-protective stem epitopesJavier G Magadán, Meghan O Altman, William L Ince, et al.
Pageof 3